Biotech Investing: Phase II is the Sweet Spot
April 20, 2011 at 06:00 AM EDT
I recently received a call from an investor relations representative who wanted to know if I'd be interested in hearing about a small biotech company with a drug candidate in Phase II trials. Obviously, I accepted. Phase II trials are my favorite time to get involved in a biotech company. I'll explain why in a moment. But first, a quick review of the phases of clinical trials...